Related Experiment Videos
Bcl-xl-specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states
B Drache1, G E Diehl, K Beyreuther
1Institute for Dementia Research, Bayer Corporation, West Haven, Connecticut 06516, USA.
Abstract:
This report describes the production of a monoclonal antibody raised against Bcl-xl, and includes an initial study of bcl-xl expression in neuropathology including Alzheimer's disease (AD). Bcl-xl is a potent apoptotic inhibitor and is known to be the predominant Bcl-x isoform in brain. To examine the expression of bcl-xl in aged brain and neurodegenerative disease, we raised a Bcl-xl-specific monoclonal antibody. In aged human brain, the highest bcl-xl expression was observed in cerebellum. By immunohistochemistry, significant bcl-xl expression was detected in reactive microglia of patients with AD and other neurological diseases such as progressive supranuclear palsy. Bcl-xl-positive microglia frequently colocalized with beta-amyloid plaques in AD and with activated astrocytes in non-AD and AD brains, suggesting a general role for Bcl-xl in regions of pathology. High levels of Bcl-xl protein might render microglia more resistant to cytotoxic environments such as areas of neurodegeneration and astrogliosis.
Insights
Researchers developed a new antibody to study Bcl-xl, a protein that inhibits cell death. This protein was found in microglia cells in Alzheimer
Area of Science:
- Neuroscience
- Immunology
- Cell Biology
Background:
- Bcl-xl is a key inhibitor of apoptosis, crucial for neuronal survival.
- It is the primary Bcl-x isoform expressed in the brain.
- Understanding Bcl-xl expression is vital in neurodegenerative diseases.
Purpose of the Study:
- To produce a specific monoclonal antibody against Bcl-xl.
- To investigate Bcl-xl expression patterns in aged human brain.
- To analyze Bcl-xl involvement in neuropathology, including Alzheimer's disease.
Main Methods:
- Development of a Bcl-xl-specific monoclonal antibody.
- Immunohistochemical analysis of Bcl-xl expression in human brain tissue.
- Colocalization studies with neuropathological markers (beta-amyloid plaques, activated astrocytes).
Main Results:
- Highest Bcl-xl expression observed in the cerebellum of aged brains.
- Significant Bcl-xl expression detected in reactive microglia in Alzheimer's disease and other neurological disorders.
- Bcl-xl-positive microglia frequently co-localized with beta-amyloid plaques and activated astrocytes.
Conclusions:
- Bcl-xl is expressed in reactive microglia within pathological areas of the brain.
- Its presence suggests a role in protecting microglia from cytotoxic environments.
- This finding implicates Bcl-xl in the response to neurodegeneration and astrogliosis.